These findings highlight the therapeutic potential of GLP1R and GIPR agonists for addressing harmful alcohol consumption and unhealthy food behaviors through shared neurobiological pathways and rising comorbidities between AUD and obesity [82]. Here, GIPR is linked to obesity due to melanocortin 4 receptor deficiency.